From Bioprocessing to the Digital Age: Chime Biologics at the Bioprocessing Summit 2026
Recently, the Bioprocessing Summit 2026 came to a successful close in Boston, USA. As a major global gathering for the bioprocessing industry, this year’s Summit brought together scientists, engineers, and industry leaders from around the world to exchange insights on cutting-edge topics including process development, scale-up, quality and analytics, digitalization, and artificial intelligence.
Chime Biologics showcased its core capabilities at the event and engaged in meaningful and in-depth discussions with clients, partners, and industry peers from around the world, exploring new possibilities for biologics manufacturing amid evolving technologies, business models, and industry dynamics.
Three Differentiated Strengths Creating Greater Value
As competition intensifies across the global CDMO landscape, clients are increasingly looking beyond manufacturing capacity alone, placing greater emphasis on supply resilience, scale and flexibility, and long-term technical expertise when selecting a manufacturing partner.
At this year’s Summit, Chime Biologics highlighted three differentiated strengths:
1) Genuine in Dual Source
Through a global manufacturing footprint, Chime Biologics strengthens supply chain resilience while leveraging the Chime Innovation Alliance to bring leading Chinese bioprocessing companies deeply into dual-source manufacturing, continuously enhancing supply chain competitiveness.
2) Megafactory Redefining Biomanufacturing
With greater scale, enhanced flexibility, and increasingly intelligent manufacturing systems, Chime Biologics is exploring a new model for the next generation of biologics manufacturing.
3) Pioneer in Biosimilar
As a pioneer with more than a decade of dedicated experience in biosimilars, Chime Biologics has built deep expertise and comprehensive capabilities spanning cell line development, process development, clinical supply, and global commercial manufacturing.
These differentiated capabilities also served as important starting points for discussions throughout the event. Chime Biologics had productive conversations with numerous clients and partners around project-specific manufacturing needs, global supply strategies, and the future of biologics manufacturing.
When AI Enters Biologics Manufacturing, It Changes More Than One Step
The theme of this year’s Bioprocessing Summit was:
“Transforming Bioprocessing for the Digital Age.”
As speakers at the Summit highlighted, digitalization, data, and AI are rapidly making their way into every stage of biologics R&D and manufacturing, from process development and scale-up to quality control and analytical testing.
Chime Biologics is embracing this significant trend and taking it further by applying AI across the biologics development lifecycle. Through the continuous advancement of the Chime AI Platform, Chime Biologics is working to progressively integrate data and artificial intelligence throughout biologics development and manufacturing.
From AI-assisted cell line development and process optimization to increasingly intelligent manufacturing operations, digital and AI technologies are helping transform biologics manufacturing from experience-driven approaches toward data-driven processes, intelligent decision-making, and continuous optimization.
From One Industry Event to New Ideas and Collaborations
We would like to thank all the clients, partners, and industry peers who visited the Chime Biologics booth during the Bioprocessing Summit 2026, and everyone who shared project needs, industry insights, and perspectives on the future with us through open and meaningful conversations.
Chime Biologics will continue to work closely with clients and partners around the world to explore new possibilities in biologics manufacturing and help advance the industry toward a future that is smarter, more efficient, and more resilient.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.
For more information, please visit www.chimebiologics.com.
